Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 6/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941597 | 0.80 | JAK2 (0.68) | JAK2NEK1CDK2NTRK1PIK3CA | |
| SCHEMBL8941465 | 0.77 | JAK2 (0.67) | JAK2CDK9CCNT1CCNA2CDK2 | |
| SCHEMBL8943089 | 0.75 | PRKD1 (0.49) | JAK2PIM1LRRK2 | |
| SCHEMBL8941373 | 0.74 | JAK2 (0.41) | JAK2NEK1CDK9CCNT1CCNA2 | |
| SCHEMBL15999471 | 0.72 | KDM4C (0.35) | CDK2MAP3K14CDC7 | |
| SCHEMBL8941384 | 0.72 | PRKD1 (0.47) | JAK2PIM1 | |
| SCHEMBL8942851 | 0.70 | JAK2 (0.65) | JAK2CDK9CCNT1CCNA2CDK2 | |
| SCHEMBL28905281 | 0.70 | JAK2 (0.73) | JAK2CDK2NTRK1KITMAP4K4 | |
| SCHEMBL8941861 | 0.69 | JAK2 (0.59) | JAK2CDK9CCNT1CCNA2CDK2 | |
| SCHEMBL8941748 | 0.69 | JAK2 (1.00) | JAK2CDK2NTRK1KITMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK2 2/4885NEK1 169/4885CDK9 85/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | JAK2 2/4885NEK1 169/4885CDK9 85/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | JAK2 2/4885NEK1 169/4885CDK9 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.